Clinical observation of docetaxel based regimens as the second-line chemotherapy in osteosarcoma

ZHU Haodong; WU Zhigang; WANG Zhen; GUO Zheng; SHI Lei; CHEN Guojing; FU Jun; LI Xiaokang

Abstract：Objective To investigate the efficacy and side effects of docetaxel based regimens as the second?line chemothera?py in osteosarcoma with lung metastasis. Methods From January 2012 to December 2013, 11 osteosarcoma patients with lung metasta?sis whom failed from first?line chemotherapy were taken docetaxel(75 mg/ m2 , d8 ) combined with gemcitabine(675 mg/ m2 , d1 , d8 ) /platinum(30 mg/ m2 , d2 ) as the second?line chemotherapy. 21 days was a cycle. The first?line chemotherapy contained cisplatin, ifos?famide, adriamycin methotrexate alternating scheme. The efficacy was evaluated by RECIST 1?? 0 criterion, and side effects were recor?ded by NCI?CTC 3?? 0 criterion. Results All patients finished treatment, and could be evaluated. There was no complete remission (CR) case, partial remission (PR) in 1 case, stable disease (SD) in 4 cases, progression of disease (PD) in 6 cases; and the re?sponse rate(RR) was 9?? 1%, disease control rate (DCR) was 45?? 5%. During the follow?up period, 3 patients died. The median pro?gression free survival time was 10?? 5 months, the median overall survival time was 18?? 0 months, and 1?year survival rate was 83?? 3%. The major adverse reactions were limiting myelosuppression during chemotherapy. There was no patients with renal dysfunction and al?lergic reaction, grade 4 neutropenia and thrombocytopenia was occured in 1 case. Conclusion Docetaxel based regimen is effective as the second?line chemotherapy in osteosarcoma with lung metastasis, and the short?term curative effect is satisfactory, toxicity can be tolerated.